Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Aug 27;27(39):5344-8.
doi: 10.1016/j.vaccine.2009.06.084. Epub 2009 Jul 14.

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans

Robert B Couch  1 , Robert L Atmar, Thomas R Cate, John M Quarles, Wendy A Keitel, Nancy H Arden, Janet Wells, Diane Niño, Philip R Wyde
Affiliations
Randomized Controlled Trial

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans

Robert B Couch et al. Vaccine. .

Abstract

To identify an adjuvant that enhances antibody responses in respiratory secretions to inactivated influenza virus vaccine (IVV), a comparison was made of responses to intranasal vaccinations of mice with IVV containing monophosphoryl lipid A (MPL), type I interferon (IFN) or cholera toxin B (CTB). Antibody in nasal secretions and lung wash fluids from mice was increased after vaccination and lung virus was significantly reduced after challenge to a similar level in each adjuvant group. Interferon was selected for a trial in humans. Trivalent inactivated influenza vaccine was given intranasally to healthy adult volunteers alone or with 1 million units (Mu) or 10 Mu of alpha interferon. Vaccinations were well tolerated but neither serum hemagglutination-inhibiting nor neutralizing antibody responses among the vaccine groups were significantly different. Similarly, neither neutralizing nor IgA antibody responses in nasal secretions were significantly different. Thus, despite exhibiting a significant adjuvant effect in mice, interferon did not exhibit an adjuvant effect for induction of antibody in respiratory secretions of humans to inactivated influenza virus vaccine given intranasally.

PubMed Disclaimer

References

    1. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine. 2008;26S:D5–D9. - PMC - PubMed
    1. Couch RB. An overview of serum antibody responses to influenza virus antigens. In: Brown F, Haaheim LR, Wood JM, Schild GC, editors. Developments in Biologicals: Laboratory Correlates of Immunity to Influenza. Vol. 115. Karger; New York: 2003. pp. 25–30. - PubMed
    1. Couch RB, Kasel JA, Six HR, Cate TR, Zahradnik JM. Immunological reactions and resistance to infection with influenza virus. In: Stuart-Harris C, Potter C, editors. Molecular Virology and Epidemiology of Influenza, Beecham Symposium. Academic Press; London: 1983. pp. 119–153.
    1. Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal antibody responses in healthy adults. J Clin Micro. 1994;32(10):2468–73. - PMC - PubMed
    1. Treanor JJ. Influenza virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. Sixth edition Elsevier Churchill Livingstone; Philadelphia: 2005. pp. 2060–85.

Publication types

MeSH terms